Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
CNS Drugs|January 4, 2020
Efficacy and Safety of Oral Therapies for Relapsing-Remitting Multiple SclerosisDamiano Paolicelli, Alessia Manni, Antonio Iaffaldano, et al.
Journal of Clinical Pharmacology|April 24, 2015
Long-term cardiac safety and tolerability of fingolimod in multiple sclerosis: A postmarketing studyDamiano Paolicelli, Alessia Manni, Vita Direnzo, et al.
Frontiers in Neurology|March 25, 2021
Longitudinal Evaluation of Serum MOG-IgG and AQP4-IgG Antibodies in NMOSD by a Semiquantitative Ratiometric MethodLuca Bollo, Pietro Iaffaldano, Maddalena Ruggieri, et al.
Brain and Behavior|October 28, 2017
Gender differences in safety issues during Fingolimod therapy: Evidence from a real-life Relapsing Multiple Sclerosis cohortAlessia Manni, Vita Direnzo, Antonio Iaffaldano, et al.
Frontiers in Immunology|July 2, 2019
Lymphocyte Count and Body Mass Index as Biomarkers of Early Treatment Response in a Multiple Sclerosis Dimethyl Fumarate-Treated CohortAlessia Manni, Antonio Iaffaldano, Giuseppe Lucisano, et al.
Journal of Clinical Pharmacology|November 27, 2015
Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis PatientsDamiano Paolicelli, Vita Direnzo, Alessia Manni, et al.
Brain Sciences|August 23, 2020
Effect of Cladribine on Neuronal Apoptosis: New Insight of In Vitro Study in Multiple Sclerosis TherapyMaddalena Ruggieri, Concetta Domenica Gargano, Anna Ferretta, et al.
BMC Psychology|July 29, 2025
The protective role of cognitive reserve in moderating depressive symptomatology in patients with multiple sclerosisMadia M Biasi, Paolo Taurisano, Alessia Manni, et al.
Pageof 3